Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
Castle Biosciences (NASDAQ: CSTL) announces its role as a national sponsor of The Sun Bus, a mobile clinic offering free skin checks and sun safety education. The initiative highlights skin cancer awareness, recognized as the most commonly diagnosed cancer in the U.S. In 2022, The Sun Bus will provide over 360 hours of services at more than 50 locations across various states, including Texas and Georgia. Castle's leadership emphasizes the importance of early detection and prevention in improving patient care.
- Castle Biosciences' sponsorship of The Sun Bus showcases its commitment to public health and skin cancer awareness.
- The initiative could enhance brand recognition and goodwill, potentially leading to increased market share.
- None.
The Sun Bus will make a stop at Castle’s headquarters in the
“Skin cancer is the most commonly diagnosed cancer in the U.S.,” said
The Sun Bus plans to provide over 360 hours of free skin screening services and sun safety education at more than 50 locations across
“At Castle, we are passionate about improving patient care, and that begins first with education and awareness around the importance of prevention and the early detection of skin cancer,” said
To learn more about The Sun Bus and planned stops on its 2022 tour, visit https://www.thesunbus.org/.
About The Sun Bus
The Sun Bus is a mobile clinic that offers a sun safety education experience that hyper-targets select audiences at varying times throughout the year. The program was launched in 2019 in an effort to better address the
About
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005253/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source:
FAQ
What is Castle Biosciences doing with The Sun Bus?
When will The Sun Bus be at Castle's headquarters?
In which states will The Sun Bus operate in 2022?
What is the main focus of The Sun Bus project?